Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?

Minerva Gastroenterologica e Dietologica

Volumn 53, Issue 4, 2007, Pages 337-350

  Ciesek, S ^a   Manns, M P ^a   Wedemeyer, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hepatitis; Immunosuppressive agents; Liver transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALOPECIA; ANEMIA; ARTHRALGIA; BONE MARROW DEPRESSION; DIABETES MELLITUS; DIARRHEA; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEADACHE; HEPATITIS B; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERPLASIA; HYPERTENSION; INDUCED HYPOTHERMIA; KIDNEY DISEASE; LEUKOPENIA; LIVER TOXICITY; LIVER TRANSPLANTATION; MOON FACE; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; OSTEOPOROSIS; RASH; REVIEW; SIDE EFFECT; SURVIVAL; TREMOR; VIRUS HEPATITIS; WOUND COMPLICATION;

ADRENAL CORTEX HORMONES; ADULT; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PREGNANCY; RATS; TIME FACTORS;

EID: 38649132861     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology 2006;43(2 Suppl 1):S132-44.
2. Munck A, Guyre PM. Glucocorticoid physiology, pharmacology and stress. Adv Exp Med Biol 1986;196:81-96.
3. Fries E, Hesse J, Hellhammer J, Hellhammer DH. A new view on hypocortisolism. Psychoneuroendocrinology 2005;30:1010-6.
4. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 2002;966:290-303.
5. McGeown MG, Douglas JF, Brown WA, Donaldson RA, Kennedy JA, Loughridge WG et al. Advantages of low dose steroid from the day after renal transplantation. Transplantation 1980;29:287-9.
6. Zenker R, Pichlmaier H, Erpenbeck R, Besirsky HW, Jabour A, Edel H et al. First experience with the transplantation of cadaveric kidneys in man. Munch Med Wochenschr 1967;109:613-20.
7. Bishop RC, Beal JM, Longmire WP Jr. The use of ACTH and cortisone in homografting; effect of preoperative administration of ACTH to donor and recipient on the survival of skin homografts in humans. West J Surg Obstet Gynecol 1952;60:193-8.
8. Sulek K. Nobel prize for Edward Calvin Kendall, Thaddeus Reichstein and Philip Showalter Hench in 1950 for their discoveries related to adrenal cortex hormones, their structure and biological activity. Wiad Lek 1968;21:1885-7.
9. Hirschmann R. The cortisone era: aspects of its impact. Some contributions of the Merck Laboratories. Steroids 1992;57:579-92.
10. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 2002;68-69:433-55.
11. Aderem AA, Rosen A, Barker KA. Modulation of prostaglandin and leukotriene biosynthesis. Curr Opin Immunol 1988;1:56-62.
12. Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 1991;11:119S-25S.
13. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-48.
14. Calne RY. Organ transplantation. The present position and future prospects of organ transplantation. Trans Med Soc Lond 1969;85:56-67.
15. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006;57:119-37.
16. Gombar VK, Enslein K, Blake BW. Carcinogenicity of azathioprine: an S-AR investigation. Mutat Res 1993;302:7-12.
17. Abel EA. Cutaneous manifestations of immunosuppression in organ transplant recipients. J Am Acad Dermatol 1989;21(2 Pt 1):167-79.
18. Patel P, Moazzam N, Potti A, Mehdi SA. Azathioprine induced hodgkin lymphoma: a case report and review of literature. Am J Clin Oncol 2005;28:427-8.
19. Thomas DB. Steroid hormones and medications that alter cancer risks. Cancer 1988;62(8 Suppl):1755-67.
20. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
21. IARC monograph programme on the evaluation of the carcinogenic risk of chemicals to humans: preamble. IARC Monogr Eval Carcinog Risk Chem Hum 1981;26:11-34.
22. Norgard B, Pedersen L, Fonager K, Rasmussen SN, Sorensen HT. Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003;17:827-34.
23. Sauk J, Kane S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin Pharmacother 2005;6:1833-9.
24. de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101:1390-2.
25. Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007;25:73-81.
26. Hardinger KL. Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy 2006;26:1771-83.
27. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl 2004;10:577-83.
28. Walsh CT, Zydowsky LD, McKeon FD. Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 1992;267:13115-8.
29. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
30. Zenke G, Baumann G, Wenger R, Hiestand P, Quesniaux V, Andersen E et al. Molecular mechanisms of immunosuppression by cyclosporins. Ann N Y Acad Sci 1993;685:330-5.
31. Williams D, Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 2006;13:47-55.
32. Rezzani R. Cyclosporine A and adverse effects on organs: histochemical studies. Prog Histochem Cytochem 2004;39:85-128.
33. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci 1993;696:9-19.
34. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000;7:731-48.
35. Winkler M, Pichlmayr R, Neuhaus P, McMaster P, Calne R, Otto G et al. Optimal FK 506 dosage in patients under primary immunosuppression following liver transplantation. Transpl Int 1994;7 Suppl 1:S58-63.
36. Rifai K, Kirchner GI, Bahr MJ, Cantz T, Rosenau J, Nashan B et al. A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation. Liver Transpl 2006;12: 411-5.
37. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995;17:615-20.
38. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp 2003;252: 279-86; discussion 286-90.
39. Norman DJ, Chatenoud L, Cohen D, Goldman M, Shield CF 3rd. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993;25(2 Suppl 1):89-92.
40. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005;433:477-80.
41. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45.
42. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005;10:479-98.
43. Sehgal SN, Baker H, Eng CP, Singh K, Vezina C. Demethoxyrapamycin (AY-24,668), a new antifungal antibiotic. J Antibiot (Tokyo) 1983;36:351-4.
44. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28:727-32.
45. Heitman J, Movva NR, Hall MN. Proline isomerases at the crossroads of protein folding, signal transduction, and immunosuppression. New Biol 1992;4:448-60.
46. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369-91.
47. Kruger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Boger CA et al. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Transplant Proc 2007;39:518-21.
48. Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E et al. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006;10:565-9.
49. Chueh SC, Kalian BD. Clinical application of sirolimus in renal transplantation: an update. Transpl Int 2005;18:261-77.
50. Kaneda H, Taketani Y, Saito S. Sirolimus-eluting stent implantation outside a previous stent. J Invasive Cardiol 2007;19:149-51.
51. Khattab AA, Hamm CW, Senges J, Toelg R, Geist V, Bonzel T et al. Incidence and predictors of target vessel revascularization after sirolimus-eluting stent treatment for proximal left anterior descending artery stenoses among 2274 patients from the prospective multicenter German Cypher Stent Registry. Clin Res Cardiol 2007 Feb 26; [Epub ahead of print].
52. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L; et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
53. Kolhe N, Mamode N, Van der Walt J, Pattison J. Regression of post-transplant Kaposi's sarcoma using sirolimus. Int J Clin Pract 2006;60:1509-12.
54. Andrassy J, Graeb C, Rentsch M, Jauch KW, Guba M. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005;80(1 Suppl):S171-4.
55. Maheshwari A, Torbenson MS, Thuluvath PJ. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci 2006;51: 1677-84.
56. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-58.
57. Levy G, Schmidli H, Punch J, Tuttle-Newhall E, Mayer D, Neuhaus P et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006;12:1640-8.
58. Henry ML, Rajab A. The use of basiliximab in solid organ transplantation. Expert Opin Pharmacother 2002;3:1657-63.
59. Marino IR, Doria C, Scott VL, Foglieni CS, Lauro A, Piazza T et al. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients. Transplantation 2004;78:886-91.
60. Yan LN, Wang W, Li B, Lu SC, Wen TF, Lin QY et al. Single-dose daclizumab induction therapy in patients with liver transplantation. World J Gastroenterol 2003;9:1881-3.
61. Ingle GR, Shah T. Enteric-coated mycophenolate sodium for transplant immunosuppression. Am J Health Syst Pharm 2005;62: 2252-9.
62. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005;1:505-26.
63. Wang K, Zhang H, Li Y, Wei Q, Li H, Yang Y et al. Efficacy of mycophenolate mofetil versus azathioprine after renal transplantation: a systematic review. Transplant Proc 2004;36: 2071-2.
64. Rodriguez-Luna H, Vargas HE. Natural history of hepatitis C and outcomes following liver transplantation. Minerva Gastroenterol Dietol 2004;50:51-9.
65. Belli LS, Burroughs AK, Burra P, Alberti AB, Samonakis D, Camma C et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl 2007 Mar 16; [Epub ahead of print].
66. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006;44:717-22.
67. Bourgeois N. Hepatitis C recurrence after liver transplantation. Acta Gastroenterol Belg 1999;62:428-31.
68. Berg T, Hopf U, Bechstein WO, Muller AR, Fukumoto T, Neuhaus R et al. Pretransplant virological markers hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation. Transplantation 1998;66:225-8.
69. Charlton M. Natural history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis 2003;7:585-602.
70. Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW et al. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surg Today 2003;33:421-5.
71. Benlloch S, Berenguer M, Prieto M, Rayon JM, Aguilera V, Berenguer J. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005;11:456-62.
72. Walter T, Dumortier J, Guillaud O, Hervieu V, Paliard P, Scoazec JY et al. Rejection under alpha interferon therapy in liver transplant recipients. Am J Transplant 2007;7:177-84.
73. Teixeira R, Godinho Menezes E, Schiano TD. Therapeutic management of recurrent hepatitis C after liver transplantation. Liver Int 2007;27:302-12.
74. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo G et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007;46:459-65.
75. Bizollon T, Pradat P, Mabrut JY, Radenne S, Ducerf C, Baulieux J et al. Histological benefit of retreatment by pegylated interferon alfa-2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation. Am J Transplant 2007;7:448-53.
76. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479-89.
77. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006;6:2348-55.
78. Sharma P, Lok A. Viral hepatitis and liver transplantation. Semin Liver Dis 2006;26:285-97.
79. Rosenau J, Kreutz T, Kujawa M, Bahr MJ, Rifai K, Hooman N et al. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 2007;46:635-44.
80. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 2005;80(1 Suppl):S120-4.
81. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, KlempnauerJ, Manns MP et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34: 895-902.
82. Matthews SJ. Entecavir for the treatment of chronic-hepatitis B virus infection. Clin Ther 2006;28:184-203.
83. Marubashi S, Dono K, Miyamoto A, Takeda Y, Nagano H, Umeshita K et al. Liver transplantation for hepatitis C. J Hepatobiliary Pancreat Surg 2006;13:382-92.
84. Sheiner PA, Florman SS, Emre S, Fishbein T, Schwartz ME, Miller CM et al. Recurrence of hepatitis C after liver transplantation is associated with increased systemic IL-10 levels. Mediators Inflamm 2001;10:37-41.
85. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V. D'Errico A et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-8.
86. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003;9:S58-62.
87. Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl 2006; 12(11 Suppl 2):S38-47.
88. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pyrsopoulos N et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. Transplantation 2007 Oct 15;84:829-35.
89. Klintmalm GB, Washburn WK, Rudich SM, Heffron TG, Teperman LW, Fasola C et al. Corticosteroid-free immunosuppression with declizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study. Liver Transpl 2007 Nov 13;13:1521-31.
90. Vivarelli M, Burra P, Barba GL, Canova D, Senzolo M, Cucchetti A et al. Influence of steroids on HCV recurrence after liver transplantation: a prospective study. J Hepatol 2007 Sep 24;[Epub ahead of print].
91. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco D, Olaso V et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998;28:756-63.
92. Hunt J, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001;7:1056-63.
93. Mueller AR, Platz KP, Blumhardt G, Bechstein WO, Steinmuller T, Christe W et al. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? Clin Transplant 1995;9(3 Pt 1):176-84.
94. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65:1044-6.
95. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-9.
96. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8.
97. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131:1452-62.
98. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-41.
99. El-Farrash MA, Aly HH, Watashi K, Hijikata M, Egawa H, Shimotohno K. In vitro infection of immortalized primary hepatocytes by HCV genotype 4a and inhibition of virus replication by cyclosporin. Microbiol Immunol 2007;51:127-33.
100. Ma S, Boerner JE, TiongYip C, Weidmann B, Ryder NS, Cooreman MP et al. NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother 2006;50:2976-82.
101. Hilgard P, Kahraman A, Lehmann N, Seltmann C, Beckebaum S, Ross RS et al. Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation: effects on virus replication and recurrent hepatitis. World J Gastroenterol 2006;12:697-702.
102. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayon JM, Benlloch S et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl 2006;12:762-7.
103. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-7.
104. Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-4.
105. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999;117:1198-204.
106. Pascual J. Everolimus in clinical practice - renal transplantation. Nephrol Dial Transplant 2006;21 Suppl 3:iii18-23.
107. Cowan PA, Heizer KE. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Nephrol Nurs J 2000;27:623-5.
108. Neff GW, Ruiz P, Madariaga JR, Nishida S, Montalbano M, Meyer D et al. Sirolimus-associated hepatotoxicity in liver transplantation. Ann Pharmacother 2004;38:1593-6.
109. Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs 2002;62:995-1011.
110. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7:1064-70.
111. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR et al. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007;138:198-204.
112. Cornberg M, Hinrichsen H, Teuber G, Berg T, Naumann U, Falkenberg C et al. Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J Hepatol 2002;37:843-7.
113. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005;11:750-9.
114. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002;8:40-6.
115. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-9.
116. Berenguer M, Wright TL. Treatment strategies for hepatitis C: intervention prior to liver transplant, pre-emptively or after established disease. Clin Liver Dis 2003;7:631-50, vii.
117. Bahra M, Neumann UI, Jacob D, Puhl G, Klupp J, Langrehr JM et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005;5:406-11.